Evidence map›Paper›PMID 31725644›Full record

ArticleMedicine2019

Effects of Chaihu-Shugan-San capsule for psychogenic erectile dysfunction: Study protocol of a randomized placebo-controlled trial.

Feiqiang Ren, Ziyang Ma, Yifeng Shen, Guangsen Li, Yaodong You, Xujun Yu, Zhengjie Li, Degui Chang, Peihai Zhang

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Feiqiang RenHospital of Chengdu University of Traditional Chinese Medicine and Chengdu University of Traditional Chinese Medicine.
Ziyang MaHospital of Chengdu University of Traditional Chinese Medicine and Chengdu University of Traditional Chinese Medicine.
Yifeng ShenHospital of Chengdu University of Traditional Chinese Medicine and Chengdu University of Traditional Chinese Medicine.
Guangsen LiThe Urology and Andrology Department, Hospital of Chengdu University of Traditional Chinese Medicine.
Yaodong YouThe Urology and Andrology Department, Hospital of Chengdu University of Traditional Chinese Medicine.
Xujun YuThe Andrology Department, The School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine.
Zhengjie LiAcupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, PR China.
Degui ChangThe Urology and Andrology Department, Hospital of Chengdu University of Traditional Chinese Medicine.
Peihai ZhangThe Urology and Andrology Department, Hospital of Chengdu University of Traditional Chinese Medicine.
Chengdu University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundErectile dysfunction (ED) affects many adult men worldwide. Many studies on the brain of psychogenic ED have shown significant cerebral functional changes and reduced volume of gray matter and white matter microstructural alterations in widespread brain regions. Chaihu-Shugan-San (CHSGS) capsule has been used to treat ED from the 20th century in China. However, clinical research of CHSGS capsule in the treatment of ED was lack. We design this study to evaluate the efficacy and safety of CHSGS capsule in the treatment of patients suffering from psychogenic ED. Furthermore, we also aim to provide a new evidence as well as an innovation of the clinical treatment in psychogenic ED.

methodsThis study is designed as a multi-center, 3-arms, randomized trial. From the perspective of psychogenic ED, we will divide patients into 3 groups, which are placebo group, tadalafil group and CHSGS group. One hundred thirty-five patients will be randomly allocated to receive placebo, CHSGS capsule or tadalafil oral pharmacotherapy. After the period of 4-week treatment, the outcome of primary assessment changes in the brain MRI, IIEF-5, EHS, and QEQ total scores from baseline. Secondary assessments include the SEAR, HAMA-14, HAMD-17 scores, response rate of the patients and their partners. DISCUSSION: We designed this study based on previous research about psychogenic erectile dysfunction (ED). This study will provide objective evidences to evaluate the effects of CHSGS capsule as an adjuvant treatment for psychogenic ED. TRIAL REGISTRATION NUMBER: chictr.org.cn, ChiCTR-IOR-1800018301.

Indexed as

Erectile DysfunctionPlant ExtractsTadalafilVasodilator AgentsAdultDouble-Blind MethodHumansMaleMulticenter Studies as TopicRandomized Controlled Trials as TopicYoung Adultchaihu-shugan-sanPlant ExtractsTadalafilVasodilator Agents

Identifiers

PMID31725644
PMCPMC6867737
OpenAlexW2987593175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.